Integrating cervical cancer and genital tract infection screening into mother, child health and family planning clinics in Eldoret, Kenya.
BACKGROUND
Visual inspection, with acetic acid (VIA) and with Lugol's iodine (VILI), has been demonstrated to have test characteristics comparable to those of Pap smear but are more affordable and easier implement. It also presents an opportunity for management of female genital tract infection.


OBJECTIVE
Pilot test integration of cervical cancer screening using visual inspection with genital tract infection identification into an existing MCH-FP in MTRH.


METHODS
Cross sectional, descriptive study in which consecutive women were screened for genital tract inflammatory morbidity and cervical cancer through visual inspection.


RESULTS
Two hundred and nineteen women with a mean age of 31-3 years, parity of 3.1 were screened. About 54% of study participants had multiple sex partners, 62% had sexual debut earlier than 20 years, while use of tobacco was reported by 4%. The test positivity rate was 13.9% and 16.9% for VIA and VILI respectively. Positive test finding was significantly related to contraceptive never-use after controlling for previous screening (p=0.006).Symptoms of genital tract infections were reported by 38% of the participants with features of cervicitis being reported by nearly 24%.


CONCLUSIONS
Integration of cervical cancer screening and genital tract infection identification and treatment into the existing MCH-FP appears feasible.
Were
E
E
Department of Reproductive Health, Moi University, Eldoret, Kenya. eowere@gmail.com
Nyaberi
Z
Z
Buziba
N
N
D000328:Adult; D000367:Age Factors; D002648:Child; D003430:Cross-Sectional Studies; D019033:Delivery of Health Care, Integrated / Q000458:organization & administration*; D005193:Family Planning Services / Q000458:organization & administration; D005260:Female; D005831:Genital Diseases, Female / Q000175:diagnosis* / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D007630:Kenya / Q000453:epidemiology; D008403:Mass Screening / Q000706:statistics & numerical data; D008430:Maternal-Child Health Centers / Q000458:organization & administration; D010865:Pilot Projects; D012307:Risk Factors; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis* / Q000453:epidemiology / Q000517:prevention & control; D055815:Young Adult; D002578:Uterine Cervical Dysplasia / Q000175:diagnosis* / Q000517:prevention & control
Acta Obstet Gynecol Scand. 2006;85(3):343-9
16553184
J Low Genit Tract Dis. 2001 Jan;5(1):24-8
17043558
Health Policy Plan. 1996 Dec;11(4):339-53
10164192
East Afr Med J. 2002 Jan;79(1):16-21
12380865
Int J Cancer. 2004 Jul 20;110(6):907-13
15170675
Soc Sci Med. 2002 Jan;54(1):105-17
11820674
Cytopathology. 2006 Dec;17(6):348-52
17168917
Am J Obstet Gynecol. 2007 Apr;196(4):407.e1-8; discussion 407.e8-9
17403438
Cancer Epidemiol Biomarkers Prev. 1998 Mar;7(3):237-41
9521440
East Afr Med J. 2001 Feb;78(2):55-9
11682945
Stud Fam Plann. 1997 Jun;28(2):95-103
9216030
Eur J Gynaecol Oncol. 2004;25(6):689-98
15597844
Lancet. 1995 Aug 26;346(8974):530-6
7658778
Int J Cancer. 2008 Jul 1;123(1):153-60
18404671
Afr J Reprod Health. 2001 Dec;5(3):29-46
12471927
Clin Trials. 2008;5(5):496-503
18827042
Eur J Gynaecol Oncol. 2008;29(3):205-21
18592782
East Afr Med J. 1996 Oct;73(10):675-8
8997849
Aust N Z J Obstet Gynaecol. 2007 Feb;47(1):54-60
17261102